The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial): Final results.
E. Mitry
Consultant or Advisory Role - Roche
Honoraria - Pfizer; Roche
O. Bouche
Consultant or Advisory Role - Pfizer (U)
J. Seitz
No relevant relationships to disclose
P. Etienne
No relevant relationships to disclose
J. Legoux
Honoraria - Roche
Other Remuneration - Pfizer
T. Aparicio
No relevant relationships to disclose
G. Breysacher
No relevant relationships to disclose
C. Lecaille
No relevant relationships to disclose
T. Lecomte
No relevant relationships to disclose
J. Jouve
No relevant relationships to disclose